NeuroSense Therapeutics Ltd (NASDAQ:NRSN)’s traded shares stood at 0.3 million during the last session, with the company’s beta value hitting 1.52. At the close of trading, the stock’s price was $1.52, to imply an increase of 4.11% or $0.06 in intraday trading. The NRSN share’s 52-week high remains $1.63, putting it -7.24% down since that peak but still an impressive 66.45% since price per share fell to its 52-week low of $0.51.

NeuroSense Therapeutics Ltd (NASDAQ:NRSN) trade information

After registering a 4.11% upside in the last session, NeuroSense Therapeutics Ltd (NRSN) has traded red over the past five days. The 5-day price performance for the stock is 15.15%, and 52.00% over 30 days. With these gigs, the year-to-date price performance is 26.67%.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 2.71% for the past 5-year period. While 2025 is set for a 16.83% return in earnings, projections for the next 5 years are at 27.32% annually.

NRSN Dividends

NeuroSense Therapeutics Ltd has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

The next major institution holding the largest number of shares is MEITAV INVESTMENT HOUSE LTD with 40000.0 shares, or about 0.2597% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $44800.0.

Going by data provided on Mar 31, 2025 , Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund holds roughly 15.87 shares. This is just over 0.07% of the total shares, with a market valuation of $24122.0